Angel investing is on the rise, with global activity expected to reach just shy of $35 billion in 2026, up from $31 billion in 2025.

Yaniv Sneor, founder of Mid Atlantic Bio Angels and CEO of Native State Therapeutics, Alexander Kimmet, a director at 37 Angels, and Jo Ann Corkran, Co-CEO and a managing partner of Golden Seeds, will discuss what is driving increased activity in angel investing and why it is a source of funding that the alternative investment community shouldn’t ignore. The discussion will be facilitated by Arina Shulga, a partner at Fox Rothschild.

Topics discussed will include:

• A look at angel investing as an alternative asset class
• Advantages of specialization
• Differentiation from VCs and traditional funds
• Ways to engage

Speakers:
Arina Shulga, Partner, Fox Rothschild
Alexander Kimmet, Director, 37 Angels
Yaniv Sneor, Co-Founder, BioAngels